241 related articles for article (PubMed ID: 22595378)
61. Routine cervical length and fetal fibronectin screening in asymptomatic twin pregnancies: is there clinical benefit?
Lifshitz SJ; Razavi A; Bibbo C; Rebarber A; Roman AS; Saltzman DH; Fox NS
J Matern Fetal Neonatal Med; 2014 Apr; 27(6):566-70. PubMed ID: 23919826
[TBL] [Abstract][Full Text] [Related]
62. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
Manuck TA
Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
[TBL] [Abstract][Full Text] [Related]
63. The effect of blood staining on cervicovaginal quantitative fetal fibronectin concentration and prediction of spontaneous preterm birth.
Hezelgrave NL; Kuhrt K; Cottam K; Seed PT; Tribe RM; Shennan AH
Eur J Obstet Gynecol Reprod Biol; 2017 Jan; 208():103-108. PubMed ID: 27918947
[TBL] [Abstract][Full Text] [Related]
64. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
Hall NR
Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799
[TBL] [Abstract][Full Text] [Related]
65. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
Joy S; Rhea DJ; Istwan NB; Desch CN; Stanziano G
Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
[TBL] [Abstract][Full Text] [Related]
66. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.
Spong CY; Meis PJ; Thom EA; Sibai B; Dombrowski MP; Moawad AH; Hauth JC; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S;
Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1127-31. PubMed ID: 16157124
[TBL] [Abstract][Full Text] [Related]
67. Does progesterone treatment influence risk factors for recurrent preterm delivery?
Meis PJ; Klebanoff M; Dombrowski MP; Sibai BM; Leindecker S; Moawad AH; Northen A; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S
Obstet Gynecol; 2005 Sep; 106(3):557-61. PubMed ID: 16135587
[TBL] [Abstract][Full Text] [Related]
68. Correlation of cervical length, fetal fibronectin, phIGFBP-1, and cytokines in spontaneous preterm birth up to 14 days from sampling.
Hadži-Lega M; Markova AD; Stefanovic M; Tanturovski M
J Perinat Med; 2015 Sep; 43(5):545-51. PubMed ID: 25503663
[TBL] [Abstract][Full Text] [Related]
69. The Effect of Intramuscular 17α-Hydroxyprogesterone in Women Screened for Shortened Cervical Length.
Wood SL; Williams BN; Szychowski JM; Owen J
Am J Perinatol; 2020 Jun; 37(7):659-665. PubMed ID: 31756763
[TBL] [Abstract][Full Text] [Related]
70. The diagnostic value of fetal fibronectin testing in clinical practice.
Cornelissen LGH; van Oostrum NHM; van der Woude DAA; Rolf C; Porath MM; Oei SG; van Laar JOEH
J Obstet Gynaecol Res; 2020 Mar; 46(3):405-412. PubMed ID: 31955485
[TBL] [Abstract][Full Text] [Related]
71. [Fetal fibronectin and cervical length as early predictors of preterm labor].
López Farfán JA; Sánchez Tovar HB; Gutiérrez de Anda Mdel R; Gámez Guevara C
Ginecol Obstet Mex; 2011 Jun; 79(6):337-43. PubMed ID: 21966824
[TBL] [Abstract][Full Text] [Related]
72. The use of quantitative fetal fibronectin for the prediction of preterm birth in women with exposed fetal membranes undergoing emergency cervical cerclage.
Suff N; Hall M; Shennan A; Chandiramani M
Eur J Obstet Gynecol Reprod Biol; 2020 Mar; 246():19-22. PubMed ID: 31923878
[TBL] [Abstract][Full Text] [Related]
73. Quantitative fetal fibronectin testing in combination with cervical length measurement in the prediction of spontaneous preterm delivery in symptomatic women.
Bruijn M; Vis JY; Wilms FF; Oudijk MA; Kwee A; Porath MM; Oei G; Scheepers H; Spaanderman M; Bloemenkamp K; Haak MC; Bolte AC; Vandenbussche F; Woiski MD; Bax CJ; Cornette J; Duvekot JJ; Nij Bijvanck B; van Eyck J; Franssen M; Sollie KM; van der Post J; Bossuyt P; Opmeer BC; Kok M; Mol B; van Baaren GJ
BJOG; 2016 Nov; 123(12):1965-1971. PubMed ID: 26667313
[TBL] [Abstract][Full Text] [Related]
74. Fetal fibronectin as a predictor of spontaneous preterm labour in asymptomatic women with a cervical cerclage.
Duhig KE; Chandiramani M; Seed PT; Briley AL; Kenyon AP; Shennan AH
BJOG; 2009 May; 116(6):799-803. PubMed ID: 19432568
[TBL] [Abstract][Full Text] [Related]
75. Obstetric management of moderate and late preterm labour.
McParland PC
Semin Fetal Neonatal Med; 2012 Jun; 17(3):138-42. PubMed ID: 22410256
[TBL] [Abstract][Full Text] [Related]
76. Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice.
Rebarber A; Fox NS; Klauser CK; Istwan NB; Rhea DJ; Stanziano GJ; Saltzman DH
J Matern Fetal Neonatal Med; 2010 Oct; 23(10):1139-42. PubMed ID: 20170407
[TBL] [Abstract][Full Text] [Related]
77. Fetal fibronectin detection for preterm birth prediction.
Gao L; Zhang JP; Chen H; Guo ZJ; Chen LB; Tan JP; Wang YH; Zhang R; Liu YL; Cai WB
Genet Mol Res; 2014 Feb; 13(1):1323-8. PubMed ID: 24634230
[TBL] [Abstract][Full Text] [Related]
78. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study.
Shennan A; Crawshaw S; Briley A; Hawken J; Seed P; Jones G; Poston L
BJOG; 2006 Jan; 113(1):65-74. PubMed ID: 16398774
[TBL] [Abstract][Full Text] [Related]
79. The short-term prediction of preterm birth: a systematic review and diagnostic metaanalysis.
Boots AB; Sanchez-Ramos L; Bowers DM; Kaunitz AM; Zamora J; Schlattmann P
Am J Obstet Gynecol; 2014 Jan; 210(1):54.e1-54.e10. PubMed ID: 24021995
[TBL] [Abstract][Full Text] [Related]
80. Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.
Mason MV; Poole-Yaeger A; Krueger CR; House KM; Lucas B
Manag Care; 2010 Feb; 19(2):46-52. PubMed ID: 20550052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
